Sugi Predict

Sugi Predict / Compounds / SCHEMBL368074

SCHEMBL368074

SCHEMBL368074

CC(C)(C)OC(=O)NCCCCCCCN

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.71
▸ MAOA P21397 1/20 0.66
▸ MAOB P27338 1/20 0.66
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ CA1 P00915 8/20 0.56
▸ CA2 P00918 8/20 0.56
▸ CA12 O43570 6/20 0.56
▸ CA9 Q16790 6/20 0.56
▸ PAOX Q6QHF9 2/20 0.55
▸ EPHX1 P07099 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989107 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL964035 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL1309451 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL1206249 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL146037 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL5866373 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL220281 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL1286925 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
Hydrochloric Acid SCHEMBL2417149 0.98 TDP1 (0.69) TDP1MAOAMAOBMEN1KMT2A
Hydrochloric Acid SCHEMBL3231613 0.98 TDP1 (0.69) TDP1MAOAMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118831053-A Nanometer delivery system of nucleotide drug and preparation method and application thereof 中国科学院苏州纳米技术与纳米仿生研究所 2024-10-25 — — CN claimed
CN-118005556-A COX-2 targeted inhibition photosensitizer capable of activating tumor cell apoptosis and preparation method and application thereof 大连理工大学 2024-05-10 — — CN claimed
CN-116574081-B Chlorogenic acid-Huang Qinsu conjugate and preparation method and application thereof 江西省科学院应用化学研究所 2023-09-05 — — CN claimed
CN-116574081-A Chlorogenic acid-Huang Qinsu conjugate and preparation method and application thereof 江西省科学院应用化学研究所 2023-08-11 — — CN claimed
WO-2026099594-A1 THERAPEUTIC BIFUNCTIONAL AGENTS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2026-05-15 — — WO disclosed
CN-122036705-A PROTAC compound of targeted PI3K alpha and preparation and application thereof 三亚深海化合物资源中心 2026-05-15 — — CN disclosed
EP-4673438-A1 PROTEOLYSIS-TARGETING CHIMERAS Tocris Cookson Limited (GB) 2026-01-07 — — EP disclosed
US-12479840-B2 HMG-CoA reductase degradation inducing compound UPPTHERA INC. (KR) 2025-11-25 — — US disclosed
EP-4650348-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR Mitsubishi Tanabe Pharma Corporation (JP) 2025-11-19 — — EP disclosed
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-10 — — US disclosed
CN-119677788-A Polymer contrast medium 兴和株式会社 2025-03-21 — — CN disclosed
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-03-06 — — US disclosed
US-20080318995-A1 N-Substituted Indenoisoquinolines and Syntheses Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-25 — — US disclosed
EP-1960366-A2 N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF Purdue Research Foundation (US) 2008-08-27 — — EP disclosed
WO-2007059008-A2 N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2007-05-24 — — WO disclosed
US-7183392-B2 Site-specific, covalent bioconjugation of proteins ZYOMYX, INC. (US) 2007-02-27 — — US disclosed
US-6794389-B2 Quinazoline derivatives and drugs NIPPON SHINYAKU CO., LTD. (JP) 2004-09-21 — — US disclosed
US-20030119855-A1 Heterocycle derivatives and drugs NIPPON SHINYAKU CO., LTD. (JP) 2003-06-26 — — US disclosed
EP-1306372-A1 HETEROCYCLE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2003-05-02 — — EP disclosed
WO-1997020821-A1 HETEROARYL DERIVATIVES NOVARTIS AG (CH) 1997-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318995-A1 N-Substituted Indenoisoquinolines and Syntheses Thereof GNAQ, NRAS, NPM1 TDP1 1868/4885MAOA 1700/4885MAOB 937/4885
US-20030119855-A1 Heterocycle derivatives and drugs OPRL1, OPRK1, OPRD1 TDP1 3703/4885MAOA 2158/4885MAOB 1906/4885
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF NCOR2, NSD2, NCOR1 TDP1 1801/4885MAOA 4206/4885MAOB 3975/4885
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 TDP1 443/4885MAOA 2622/4885MAOB 2338/4885
US-12479840-B2 HMG-CoA reductase degradation inducing compound HMGCR, HMGB2, LDLR TDP1 3530/4885MAOA 1164/4885MAOB 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.